Urinary TGF-β1 as an indicator of antiproteinuric response to angiotensin II receptor blocker in proteinuric renal diseases

Biomedicine and Pharmacotherapy

Volumn 63, Issue 9, 2009, Pages 672-678

  Park, Hyeong Cheon ^a   Choi, Hoon Young ^a   Kim, Beom Seok ^a   An, Hye Rim ^a   Lee, Jae Sung ^a   Ha, Sung Kyu ^a   Han, Dae Suk ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Losartan; Proteinuria; Urinary transforming growth factor 1

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIURETIC AGENT; LOSARTAN; POTASSIUM; SODIUM; TRANSFORMING GROWTH FACTOR BETA1; URIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

ADULT; ARTICLE; BIOCHEMISTRY; BLOOD ANALYSIS; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIET RESTRICTION; DRUG EFFICACY; FEMALE; GLOMERULONEPHRITIS; HEMATURIA; HUMAN; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; PREDICTION; PRIORITY JOURNAL; PROTEINURIA; TREATMENT DURATION; TREATMENT OUTCOME; URINALYSIS; BLOOD PRESSURE; DRUG EFFECT; MIDDLE AGED; URINE;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; FEMALE; HUMANS; LOSARTAN; MALE; MIDDLE AGED; PROTEINURIA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 72649092784     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2009.02.002     Document Type: Article

References (36)

1. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349 (1997) 1857-1863
2. Taal M.W., and Brenner B.M. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 57 (2000) 1803-1817
3. Donadio J.V., Bergstralh E.J., Grande J.P., and Rademcher D.M. Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol Dial Transplant 17 (2002) 1197-1203
4. Lea J., Greene T., Hebert L., Lipkowitz M., Massry S., Middleton J., et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 165 (2005) 947-953
5. Atkins R.C., Briganti E.M., Lewis J.B., Hunsicker L.G., Braden G., Champion de Crespigny P.J., et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 45 (2005) 281-287
6. de Zeeuw D., Remuzzi G., Parving H.H., Keane W.F., Zhang Z., Shahinfar S., et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65 (2004) 2309-2320
7. de Zeeuw D., Remuzzi G., Parving H.H., Keane W.F., Zhang Z., Shahinfar S., et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110 (2004) 921-927
8. Heeg J.E., de Jong P.E., van der Hem G.K., and de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 36 (1989) 272-279
9. Bos H., Andersen S., Rossing P., De Zeeuw D., Parving H.H., De Jong P.E., et al. Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney Int 75 Suppl (2000) S32-S37
10. De Jong P.E., Navis G., and de Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet 354 (1999) 352-353
11. Wolf G. Link between angiotensin II and TGF-beta in the kidney. Miner Electrolyte Metab 24 (1998) 174-180
12. Yamamoto T., Noble N.A., Miller D.E., and Border W.A. Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int 45 (1994) 916-927
13. Noh J.W., Wiggins R., and Phan S.H. Urine transforming growth factor-beta activity is related to the degree of scarring in crescentic nephritis in the rabbit. Nephron 63 (1993) 73-78
14. Honkanen E., Teppo A.M., Tornroth T., Groop P.H., and Gronhagen-Riska C. Urinary transforming growth factor-beta 1 in membranous glomerulonephritis. Nephrol Dial Transplant 12 (1997) 2562-2568
15. Monteiro de Freitas A.S., Coimbra T.M., Costa R.S., and Baroni E.A. Urinary transforming growth factor-beta (TGF-beta) excretion and renal production of TGF-beta in rats with subtotal renal ablation: effect of enalapril and nifedipine. Nephron 78 (1998) 302-309
16. Minutolo R., Balletta M.M., Catapano F., Chiodini P., Tirino G., Zamboli P., et al. Mesangial hypercellularity predicts antiproteinuric response to dual blockade of RAS in primary glomerulonephritis. Kidney Int 70 (2006) 1170-1176
17. Remuzzi A., Perico N., Sangalli F., Vendramin G., Moriggi M., Ruggenenti P., et al. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol 276 (1999) F457-F466
18. Gansevoort R.T., Sluiter W.J., Hemmelder M.H., de Zeeuw D., and de Jong P.E. Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials. Nephrol Dial Transplant 10 (1995) 1963-1974
19. Woo K.T., Lau Y.K., Wong K.S., and Chiang G.S. ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis. Kidney Int 58 (2000) 2485-2491
20. Hou F.F., Xie D., Zhang X., Chen P.Y., Zhang W.R., Liang M., et al. Renoprotection of optimal antiproteinuric doses (ROAD) study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 18 (2007) 1889-1898
21. Kramer A.B., Laverman G.D., van Goor H., and Navis G. Inter-individual differences in anti-proteinuric response to ACEI in established adriamycin nephrotic rats are predicted by pretreatment renal damage. J Pathol 201 (2003) 160-167
22. Ellis D., Forrest K.Y., Erbey J., and Orchard T.J. Urinary measurement of transforming growth factor-beta and type IV collagen as new markers of renal injury: application in diabetic nephropathy. Clin Chem 44 (1998) 950-956
23. Yamamoto T., Noble N.A., Cohen A.H., Nast C.C., Hishida A., Gold L.I., et al. Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int 49 (1996) 461-469
24. Park H.C., Xu Z.G., Choi S., Goo Y.S., Kang S.W., Choi K.H., et al. Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy. Nephrol Dial Transplant 18 (2003) 1115-1121
25. Haramaki R., Tamaki K., Fujisawa M., Ikedo H., Haramaki N., and Okuda S. Steroid therapy and urinary transforming growth factor-beta1 in IgA nephropathy. Am J Kidney Dis 38 (2001) 1191-1198
26. Coimbra T., Wiggins R., Noh J.W., Merritt S., and Phan S.H. Transforming growth factor-beta production in anti-glomerular basement membrane disease in the rabbit. Am J Pathol 138 (1991) 223-234
27. Tsakas S., and Goumenos D.S. Accurate measurement and clinical significance of urinary transforming growth factor-beta1. Am J Nephrol 26 (2006) 186-193
28. Houlihan C.A., Akdeniz A., Tsalamandris C., Cooper M.E., Jerums G., and Gilbert R.E. Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care 25 (2002) 1072-1077
29. Bertoluci M.C., Uebel D., Schmidt A., Thomazelli F.C., Oliveira F.R., and Schmid H. Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy. Diabetes Res Clin Pract 72 (2006) 258-264
30. Laverman G.D., Henning R.H., de Jong P.E., Navis G., and de Zeeuw D. Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am J Kidney Dis 38 (2001) 1381-1384
31. Klahr S., and Morrissey J.J. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int 75 Suppl (2000) S7-14
32. Burton C., and Harris K.P. The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis 27 (1996) 765-775
33. Cortes P., Riser B.L., Zhao X., and Narins R.G. Glomerular volume expansion and mesangial cell mechanical strain: mediators of glomerular pressure injury. Kidney Int 45 Suppl (1994) S11-S16
34. Lax D.S., Benstein J.A., Tolbert E., and Dworkin L.D. Effects of salt restriction on renal growth and glomerular injury in rats with remnant kidneys. Kidney Int 41 (1992) 1527-1534
35. Gansevoort R.T., de Zeeuw D., and de Jong P.E. Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease. Nephrol Dial Transplant 10 (1995) 497-504
36. Ying W.Z., and Sanders P.W. Dietary salt modulates renal production of transforming growth factor-beta in rats. Am J Physiol 274 (1998) F635-F641